The Wellness Company reports clinical benefits from Ivermectin and Mebendazole cancer study

Dr. Peter McCullough and colleagues at The Wellness Company have published a study investigating the use of a compounded combination of Ivermectin and Mebendazole in cancer patients.

The study involved 197 patients prescribed 25mg of Ivermectin and 250mg of Mebendazole. Among the 122 patients who completed a six-month follow-up, 84.4% reported clinical benefit, defined as no evidence of disease, tumor shrinkage, or stable disease. Specifically, 48.4% of those patients reported tumor shrinkage or no current evidence of disease.

The researchers suggest a dual-action mechanism where Ivermectin disrupts tumor growth pathways and triggers apoptosis, while Mebendazole blocks glucose absorption in abnormal cells. Most reported side effects were described as mild.